Based on the investigation of oncogenic mechanisms of MIBC and ABC in the previous sections, we separately chose biomarkers NFKB1, LEF1 and MYC, and biomarkers LEF1, MYC, NOTCH1 and FOXO1 as drug targets for MIBC and ABC, and then searched for small compounds that could be suitable for potential drug combination therapies with adequate regulation ability, sensitivity and toxicity to reverse the expression levels of the biomarkers. Here, LEF1 is linked to aneurysmal bone cyst.